Tschöp Johannes, Dattilo Jonathan R, Prakash Priya S, Kasten Kevin R, Tschöp Matthias H, Caldwell Charles C
Department of Surgery, University of Cincinnati College of Medicine, OH 45267, USA.
Endocr Metab Immune Disord Drug Targets. 2010 Dec;10(4):336-47. doi: 10.2174/1871530311006040336.
Sepsis, which is defined as a systemic inflammatory response syndrome that occurs during infection, is associated with several clinical conditions and high mortality rates. As sepsis progresses immune paralysis can become severe, leaving an already vulnerable patient ill equipped to eradicate primary or secondary infections. At present the predominant treatments for sepsis have not demonstrated convincing efficacy of decreased mortality. During sepsis, it has been observed that leptin levels initially increase but subsequently decline. A body of evidence has demonstrated that central or systemic leptin can beneficially regulate immune function. In this report expression of leptin and its receptor, signaling, and function on leukocytes will be reviewed. Furthermore, the effects mediated by central and systemic leptin during sepsis will be reviewed. Altogether, the ability of leptin to beneficially enhance inflammation and the host response during sepsis supports its use as a therapeutic agent, particularly during the latter phases of the syndrome.
脓毒症被定义为感染期间发生的全身性炎症反应综合征,与多种临床病症及高死亡率相关。随着脓毒症进展,免疫麻痹会变得严重,使本就脆弱的患者难以根除原发性或继发性感染。目前,脓毒症的主要治疗方法尚未显示出令人信服的降低死亡率的疗效。在脓毒症期间,已观察到瘦素水平最初升高但随后下降。大量证据表明,中枢性或全身性瘦素可有益地调节免疫功能。在本报告中,将综述瘦素及其受体在白细胞上的表达、信号传导和功能。此外,还将综述脓毒症期间中枢性和全身性瘦素介导的效应。总之,瘦素在脓毒症期间有益地增强炎症和宿主反应的能力支持将其用作治疗剂,尤其是在该综合征的后期阶段。